Tofacitinib Citrate for the Treatment of Vitiligo
2015; American Medical Association; Volume: 151; Issue: 10 Linguagem: Inglês
10.1001/jamadermatol.2015.1520
ISSN2168-6084
AutoresBrittany G. Craiglow, Brett King,
Tópico(s)Atherosclerosis and Cardiovascular Diseases
ResumoImportance Vitiligo is a common condition that is often emotionally devastating for patients. At present, no reliably effective treatments are available. Observations Recent advances in the understanding of the pathogenesis of vitiligo suggest that Janus kinase inhibitors may be a therapeutic option. We report a case of generalized vitiligo for which treatment with tofacitinib citrate, an oral Janus kinase 1/3 inhibitor, resulted in significant repigmentation. Conclusions and Relevance The results suggest that tofacitinib and other Janus kinase inhibitors may be effective in the treatment of vitiligo. Additional studies will be needed to confirm their efficacy and to explore their safety.
Referência(s)